ACS Medicinal Chemistry Letters
Letter
(9) Gross, G.; Wicke, K.; Drescher, K. U. Dopamine D(3) receptor
antagonism–still a therapeutic option for the treatment of
schizophrenia. Naunyn-Schmiedeberg's Arch. Pharmacol. 2013, 386,
155−66.
(10) Elgueta, D.; Aymerich, M. S.; Contreras, F.; Montoya, A.;
Celorrio, M.; Rojo-Bustamante, E.; Riquelme, E.; Gonzalez, H.;
Vasquez, M.; Franco, R.; Pacheco, R. Pharmacologic antagonism of
dopamine receptor D3 attenuates neurodegeneration and motor
impairment in a mouse model of Parkinson’s disease. Neuro-
pharmacology 2017, 113, 110−123.
AUTHOR INFORMATION
Corresponding Author
ORCID
■
Author Contributions
(11) Higley, A. E.; Spiller, K.; Grundt, P.; Newman, A. H.; Kiefer, S.
W.; Xi, Z. X.; Gardner, E. L. PG01037, a novel dopamine D3 receptor
antagonist, inhibits the effects of methamphetamine in rats. J.
Psychopharmacol. 2011, 25, 263−73.
The manuscript was written through contributions of all
authors. All authors have given approval to the final version of
the manuscript.
Notes
(12) Xi, Z. X.; Gardner, E. L. Pharmacological actions of NGB 2904,
a selective dopamine D3 receptor antagonist, in animal models of
drug addiction. CNS Drug Rev. 2007, 13, 240−59.
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
(13) Paterson, N. E.; Vocci, F.; Sevak, R. J.; Wagreich, E.; London,
E. D. Dopamine D3 receptors as a therapeutic target for
methamphetamine dependence. Am. J. Drug Alcohol Abuse 2014, 40,
1−9.
(14) Mugnaini, M.; Iavarone, L.; Cavallini, P.; Griffante, C.; Oliosi,
B.; Savoia, C.; Beaver, J.; Rabiner, E. A.; Micheli, F.; Heidbreder, C.;
Andorn, A.; Merlo Pich, E.; Bani, M. Occupancy of brain dopamine
D3 receptors and drug craving: a translational approach. Neuro-
psychopharmacology 2013, 38, 302−12.
(15) Levant, B. The D3 dopamine receptor: neurobiology and
potential clinical relevance. Pharmacol. Rev. 1997, 49, 231−52.
(16) Heidbreder, C. A.; Newman, A. H. Current perspectives on
selective dopamine D(3) receptor antagonists as pharmacotherapeu-
tics for addictions and related disorders. Ann. N. Y. Acad. Sci. 2010,
1187, 4−34.
(17) Cho, D. I.; Zheng, M.; Kim, K. M. Current perspectives on the
selective regulation of dopamine D(2) and D(3) receptors. Arch.
Pharmacal Res. 2010, 33, 1521−38.
(18) Keck, T. M.; John, W. S.; Czoty, P. W.; Nader, M. A.; Newman,
A. H. Identifying medication targets for psychostimulant addiction:
unraveling the dopamine D3 receptor hypothesis. J. Med. Chem. 2015,
58, 5361−80.
(19) Newman, A. H.; Beuming, T.; Banala, A. K.; Donthamsetti, P.;
Pongetti, K.; LaBounty, A.; Levy, B.; Cao, J.; Michino, M.; Luedtke, R.
R.; Javitch, J. A.; Shi, L. Molecular determinants of selectivity and
efficacy at the dopamine D3 receptor. J. Med. Chem. 2012, 55, 6689−
99.
(20) Ferruz, N.; Doerr, S.; Vanase-Frawley, M. A.; Zou, Y.; Chen, X.;
Marr, E. S.; Nelson, R. T.; Kormos, B. L.; Wager, T. T.; Hou, X.;
Villalobos, A.; Sciabola, S.; De Fabritiis, G. Dopamine D3 receptor
antagonist reveals a cryptic pocket in aminergic GPCRs. Sci. Rep.
2018, 8, 897.
(21) Jensen, N. H.; Roth, B. L. Massively parallel screening of the
receptorome. Comb. Chem. High Throughput Screening 2008, 11, 420−
6.
(22) Mach, R. H.; Huang, Y.; Freeman, R. A.; Wu, L.; Vangveravong,
S.; Luedtke, R. R. Conformationally-flexible benzamide analogues as
dopamine D3 and sigma 2 receptor ligands. Bioorg. Med. Chem. Lett.
2004, 14, 195−202.
(23) Mach, U. R.; Hackling, A. E.; Perachon, S.; Ferry, S.; Wermuth,
C. G.; Schwartz, J. C.; Sokoloff, P.; Stark, H. Development of novel
1,2,3,4-tetrahydroisoquinoline derivatives and closely related com-
pounds as potent and selective dopamine D3 receptor ligands.
ChemBioChem 2004, 5, 508−18.
(24) Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.;
Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V.;
Stevens, R. C. Structure of the human dopamine D3 receptor in
complex with a D2/D3 selective antagonist. Science 2010, 330, 1091−
5.
(25) Wang, S.; Che, T.; Levit, A.; Shoichet, B. K.; Wacker, D.; Roth,
B. L. Structure of the D2 dopamine receptor bound to the atypical
antipsychotic drug risperidone. Nature 2018, 555, 269−273.
■
Ki determinations and receptor binding profiles were
generously provided by the National Institute of Mental
Health’s Psychoactive Drug Screening Program, Contract #
HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP
is directed by Bryan L. Roth MD, PhD at the University of
North Carolina at Chapel Hill and Project Officer Jamie
Driscol at NIMH, Bethesda MD, USA. For experimental
ABBREVIATIONS
■
D1R, dopamine D1 receptor; D2R, dopamine D2 receptor;
D3R, dopamine D3 receptor; ECL2, extracellular loop 2; LAH,
lithium aluminum hydride; EDC, 1-ethyl-3-(3-
(dimethylamino)propyl)carbodiimide; DCM, dichlorome-
thane; TFA, trifluoroacetic acid; PDB, Protein Data Bank
REFERENCES
■
(1) Nakajima, S.; Gerretsen, P.; Takeuchi, H.; Caravaggio, F.; Chow,
T.; Le Foll, B.; Mulsant, B.; Pollock, B.; Graff-Guerrero, A. The
potential role of dopamine D(3) receptor neurotransmission in
cognition. Eur. Neuropsychopharmacol. 2013, 23, 799−813.
(2) Nevalainen, N.; Riklund, K.; Andersson, M.; Axelsson, J.; Ogren,
M.; Lovden, M.; Lindenberger, U.; Backman, L.; Nyberg, L. COBRA:
A prospective multimodal imaging study of dopamine, brain structure
and function, and cognition. Brain Res. 2015, 1612, 83−103.
(3) Nieoullon, A.; Coquerel, A. Dopamine: a key regulator to adapt
action, emotion, motivation and cognition. Curr. Opin. Neurol. 2003,
16 (Suppl 2), S3−9.
(4) Jackson, D. M.; Westlind-Danielsson, A. Dopamine receptors:
molecular biology, biochemistry and behavioural aspects. Pharmacol.
Ther. 1994, 64, 291−370.
(5) Zawilska, J. B. [Dopamine receptors–structure, characterization
and function]. Hig. Med. Dosw. 2003, 57, 293−322.
(6) Boateng, C. A.; Bakare, O. M.; Zhan, J.; Banala, A. K.; Burzynski,
C.; Pommier, E.; Keck, T. M.; Donthamsetti, P.; Javitch, J. A.; Rais,
R.; Slusher, B. S.; Xi, Z. X.; Newman, A. H. High affinity dopamine
D3 receptor (D3R)-selective antagonists attenuate heroin self-
administration in wild-type but not D3R knockout mice. J. Med.
Chem. 2015, 58, 6195−213.
(7) You, Z. B.; Gao, J. T.; Bi, G. H.; He, Y.; Boateng, C.; Cao, J.;
Gardner, E. L.; Newman, A. H.; Xi, Z. X. The novel dopamine D3
receptor antagonists/partial agonists CAB2−015 and BAK4−54
inhibit oxycodone-taking and oxycodone-seeking behavior in rats.
Neuropharmacology 2017, 126, 190−199.
(8) Sun, X.; Gou, H. Y.; Li, F.; Lu, G. Y.; Song, R.; Yang, R. F.; Wu,
N.; Su, R. B.; Cong, B.; Li, J. QA31, a novel dopamine D3 receptor
antagonist, exhibits antipsychotic-like properties in preclinical animal
models of schizophrenia. Acta Pharmacol. Sin. 2016, 37, 322−33.
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX